Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;34(3):321-330.
doi: 10.1037/neu0000612. Epub 2019 Dec 30.

Neurocognitive intra-individual variability within HIV+ adults with and without current substance use

Miguel Arce Rentería  1 , Desiree Byrd  2 , Kelly Coulehan  1 , Caitlin Miranda  1 , Armando Fuentes  3 , Ana K Rosario  2 , Emily P Morris  2 , Monica Rivera Mindt  2
Affiliations

Neurocognitive intra-individual variability within HIV+ adults with and without current substance use

Miguel Arce Rentería et al. Neuropsychology. 2020 Mar.

Abstract

Objective: HIV infection and current substance use (SU) are linked to cognitive and functional deficits, yet findings on their combined effects are mixed. Neurocognitive intraindividual variability, measured as dispersion of scores across a neuropsychological battery, is associated with worse cognitive outcomes and functional deficits among HIV+ adults but has not been studied in the context of HIV+ adults with current SU. We hypothesized that, among HIV+ adults, current SU would be associated with greater dispersion, that greater dispersion would be associated with worse medication adherence, and that this relationship would be worse among substance users.

Method: Forty HIV+ adults completed neuropsychological, psychiatric, SU, and medical evaluations and an electronic medication adherence measure. General linear models evaluated the main effect of SU status on neurocognitive dispersion, and models stratified by SU status evaluated the effect of dispersion on medication adherence, adjusting for relevant covariates.

Results: The SU+ group showed greater dispersion than did the SU- group, t(38) = 2.74, p = .049, d = 0.81, but this association did not survive multiple comparisons. Stratified analyses indicated a negative relationship between dispersion and medication adherence among the SU+ group but not in the SU- group; however, this effect was reduced after accounting for depressive symptoms.

Conclusions: We found preliminary evidence that current SU is associated with greater neurocognitive dispersion among HIV+ adults. SU and neurocognitive dispersion may have a synergistic effect on medication adherence; however, this effect is largely accounted for by depressive symptoms. Future research should examine progression of dispersion in HIV and consequent neurocognitive and functional deficits in those with current SU. (PsycINFO Database Record (c) 2020 APA, all rights reserved).

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Relationship of substance use status and neurocognitive dispersion. * Note: Bars represent 95% confidence intervals.
Figure 2.
Figure 2.
Relationship between neurocognitive dispersion and medication adherence by substance use status. * Note: Bars represent 95% confidence intervals.
See this image and copyright information in PMC

References

    1. AARDEX Group. Medication Event Monitoring System: Sion, Switzerland.
    1. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev. ed.): Washington, DC: Author.
    1. Anderson AE, Jones JD, Thaler NS, Kuhn TP, Singer EJ, & Hinkin CH (2018). Intraindividual variability in neuropsychological performance predicts cognitive decline and death in HIV. Neuropsychology, 32(8), 966. - PMC - PubMed
    1. Basso MR, & Bornstein RA (2003). Effects of past noninjection drug abuse upon executive function and working memory in HIV infection. J Clin Exp Neuropsychol, 25(7), 893–903. doi: 10.1076/jcen.25.7.893.16489 - DOI - PubMed
    1. Beck AT, Steer RA, & Brown G (2000). BDI-II Fast Screen for Medical Patients Manual. London: The Psychological Corporation.